Holen Sie sich die Stockscreener-App
19.98
1.91%
-0.39
Gh Research Plc Aktie (GHRS) Neueste Nachrichten
(GHRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
GH Research (GHRS) Bounces 2.23% as Shares Test Key Resistance at $22.18Exhaustion Gap - newsline.com
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower-Than-Expected Operating Loss Amid Pipeline ProgressEarnings Power Value - newsline.com
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy? - simplywall.st
GH Research PLC (GHRS) Gains Ground After Testing Support, Resistance in FocusAscending Triangle - newsline.com
GH Research Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical DevelopmentReturn On Assets - newsline.com
GHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS) - Insider Monkey
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
GH Research earnings ahead: Can cash sustain Phase 3 ambitions? - Investing.com
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
(GHRS) Risk Channels and Responsive Allocation - Stock Traders Daily
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression - Stock Titan
GH Research publishes phase 2a postpartum depression results By Investing.com - Investing.com Australia
GH Research publishes phase 2a postpartum depression results - Investing.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results - Yahoo Finance UK
GHRS Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Deepens R&D InvestmentFinancial Health Score - newsline.com
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - AOL.com
GH Research (GHRS) Surges Over 7%: Testing Key Resistance at $25.19Chandelier Stop - newsline.com
GH Research (GHRS) Surges 7.19% as Breakout Above $25.19 Resistance Becomes Key TestOvernight Profile - The Legal Advocate
Certain Options of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
GHRS Q1 2026 Earnings: Wider-than-Expected Loss Underscores Clinical-Stage ChallengesEarnings Miss Streak - newsline.com
GH Research (GHRS) Jumps 3.35% as Shares Approach Key Resistance at $24.0Insider Selling Alerts - The Legal Advocate
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research Stock Moves as Market Eyes Data in Holiday Week - Bez Kabli
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression - Sahm
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression - Stock Titan
[EFFECT] GH Research PLC SEC Filing - Stock Titan
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) - Seeking Alpha
GHRS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers GH Research stock price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright lowers GH Research stock price target on dilution - Investing.com
Lynx1 and Weston Nichols report 17.4% stake in GH Research (NASDAQ: GHRS) - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS) - simplywall.st
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans - Yahoo Finance
GHRS SEC FilingsGh Research Plc 10-K, 10-Q, 8-K Forms - Stock Titan
GHRS Maintained by Cantor Fitzgerald -- Price Target Raised to $35 - GuruFocus
Lynx1 discloses 15.2% stake in GHRS (GHRS) via Schedule 13G/A - Stock Titan
GHRS Maintained by CitizensPrice Target Lowered to $39.00 - GuruFocus
Cantor Fitzgerald raises GH Research stock price target on adoption outlook - Investing.com UK
These Analysts Revise Their Forecasts On GH Research After Q1 Results - Benzinga
Canaccord reiterates GH Research stock rating on phase 3 progress By Investing.com - Investing.com Nigeria
Cantor Fitzgerald raises GH Research stock price target on adoption outlook By Investing.com - Investing.com South Africa
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):